Triasima Portfolio Management inc. Grows Position in Gilead Sciences, Inc. $GILD

Triasima Portfolio Management inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 47,187 shares of the biopharmaceutical company’s stock after acquiring an additional 8,076 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Gilead Sciences were worth $5,792,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Csenge Advisory Group grew its position in shares of Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after purchasing an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after purchasing an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. grew its position in shares of Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares during the period. Railway Pension Investments Ltd grew its position in shares of Gilead Sciences by 3.1% in the third quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at $1,274,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA gives priority review to Gilead’s once?daily bictegravir + lenacapavir HIV regimen, shortening the path to U.S. commercialization if approved — a clear revenue and de?risking catalyst. Read More.
• Positive Sentiment: Gilead completed the Arcellx acquisition (~$7.8B), adding the anito?cel cell therapy to its oncology pipeline and boosting longer?term growth optionality beyond antivirals. Read More.
• Positive Sentiment: Analyst bullishness: Morgan Stanley and other shops have raised price targets/ratings recently, signaling analyst support that can attract buyers. Read More.
• Neutral Sentiment: Gilead scheduled presentations at several investor conferences (BofA, RBC, Bernstein, Goldman Sachs) — increases visibility and provides opportunities to update guidance/portfolio progress but is informational rather than a direct catalyst. Read More.
• Neutral Sentiment: Pre?earnings coverage highlights HIV franchise strength versus cell?therapy cost/headwinds; Wall Street expects modest earnings growth into the next print — sets expectations for the upcoming report. Read More.
• Negative Sentiment: CEO Daniel O’Day sold shares under a Rule 10b5?1 plan (recent transactions disclosed), which can create short?term headline pressure even if planned. Read More.
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking more transparency on patent exclusivities — raises governance/IP scrutiny that could produce regulatory or PR noise around future exclusivity?dependent revenues. Read More.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GILD shares. Cantor Fitzgerald lowered their price objective on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 10th. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Truist Financial lifted their price objective on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $157.35.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This represents a 15.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 178,640 shares of company stock worth $26,584,250. 0.30% of the stock is owned by insiders.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $131.65 on Monday. Gilead Sciences, Inc. has a twelve month low of $95.29 and a twelve month high of $157.29. The stock has a market capitalization of $163.41 billion, a P/E ratio of 19.45, a PEG ratio of 1.74 and a beta of 0.31. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The business’s fifty day moving average price is $140.49 and its 200 day moving average price is $132.55.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter last year, the firm earned $1.90 earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a $0.82 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.